Indication
As an add-on therapy with intranasal corticosteroids (INCS) for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with systemic corticosteroids (SCS) and/or surgery do not provide adequate disease control.
Medicine details
- Medicine name:
- dupilumab (Dupixent)
- SMC ID:
- SMC2851
- Pharmaceutical company
- Sanofi
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC